Company / Depreciation & Amortization
Edgewise Therapeutics, Inc. Depreciation & Amortization History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$2.1M
FY2025
5-year range
$272.0K / $2.1M
FY2021-FY2025
Trend
+0.7%
vs FY2024
Sector context
#99 of 163
Health Care
What the data says
At $2M, Edgewise Therapeutics, Inc.'s depreciation & amortization ranks #65 of 163 in the Health Care sector. Depreciation & Amortization has increased for 5 consecutive years, from $185,000 in FY2020 to $2M in FY2025.
Based on SEC 10-K filings.
$2M in FY2025 with a 5-year CAGR of +62.3%.
Increased from $2M to $2M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +78.2%
- 5-Year CAGR
- +62.3%
- 10-Year CAGR
- -
Sector benchmark
#65 of 163 in Health CareTop 39% of 163This company $2.1M Sector average $219.4M
▼
-99.1% below sector average
Key checks
Key Insights
- Edgewise Therapeutics, Inc.'s depreciation & amortization has grown for 5 consecutive years.
- 5-year CAGR of +62.3%, indicating consistent growth.
- In FY2025, depreciation & amortization increased 0.7% year-over-year.
- Ranks #99 out of 163 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 6.82 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.1M | +0.7% |
| FY2024 | $2.1M | +33.4% |
| FY2023 | $1.6M | +321.5% |
| FY2022 | $368.0K | +35.3% |
| FY2021 | $272.0K | +47.0% |
| FY2020 | $185.0K | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026